March 17th 2023
In an interview with Targeted Oncology™, Rohan Garje, MD, discussed available therapies, how to assess risks, and manage toxicities for patients with renal cell carcinoma.
October 31st 2022
FDA Approves Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate CancerMarch 23rd 2022
The FDA has granted approval to the agent formerly known as 177Lu-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting.
Better Health-Related QOL Outcomes With Nivolumab/Cabozantinib Endure in RCC Compared to SunitinibFebruary 19th 2022
A 3-year analysis of updated data from the phase 3 CheckMAte 9ER trial shows the better health-related quality of life outcomes for patients with advanced renal cell carcinoma on nivolumab plus cabozantinib.
Multiple Immune Cell Factors Are Associated With High Rates of Response to Nivolumab/Ipilimumab in Advanced RCCFebruary 19th 2022
Three immune cell-related factors appear to impact response or lack of response to treatment with nivolumab plus ipilimumab in patients with advanced or metastatic renal cell carcinoma.
Upfront Avelumab Maintenance Demonstrates Continued OS Benefit in Advanced UCFebruary 18th 2022
An exploratory analysis of the phase 3 JAVELIN Bladder 100 trial shows that the overall survival benefit of frontline maintenance avelumab is sustained in patients with advanced urothelial cancer.
Darolutamide Remains Safe/Effective in Patients With nmCRPC and Comorbidities Receiving Concomitant MedicationsFebruary 18th 2022
In a subgroup analysis of the ARAMIS study, the safety and efficacy of darolutamide were not impacted by patients having comorbidities and receiving concomitant medications.
PFS Prolonged With Continuous Enzalutamide After AR Inhibitor Progression in mCRPCFebruary 18th 2022
According to results from the phase 3b PRESIDE trial, use of continuous enzalutamide may extend progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.
TAK-700 Achieves Limited Overall Survival Improvement in mHSPCJune 8th 2021
Data from the phase 2 the phase 3 SWOG S1216 presented during the ASCO Annual Meeting shows numerical overall survival improvement with he experimental combination that missed the threshold for statistical significance.
Urothelial Cancer Guidelines Are Updated to Include Immune Checkpoint InhibitorsMay 17th 2021
Immunotherapies are now accepted treatments in the maintenance and second-line settings for patients with metastatic urothelial cancer and in the setting of superficial UC–carcinoma in situ with prior intravesical therapy, according to updated NCCN guidelines